SEC Form 4 · accession 0001179110-17-014585
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Marion Dorsch
Officer — Chief Scientific Officer
Period of report
Nov 21, 2017
Accepted (ET)
Nov 22, 2017 · 5:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2017 | M | 18,334 | $37.11 | A | 18,334 | D | |
| Common StockF3 | Nov 21, 2017 | S | 1,601 | $66.81 | D | 16,733 | D | |
| Common StockF4 | Nov 21, 2017 | S | 4,750 | $65.81 | D | 11,983 | D | |
| Common StockF5 | Nov 21, 2017 | S | 11,483 | $65.16 | D | 500 | D | |
| Common StockF6 | Nov 21, 2017 | S | 500 | $64.44 | A | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $37.11 | Nov 21, 2017 | M | 18,334 | D | — | Nov 21, 2026 | Common Stock | 18,334 | 91,666 | D |
Explanation of responses
- F1The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on June 22, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted on June 22, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.51 to $67.49 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 6 to this Form 4.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.44 to $66.42 per share.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.54 to $65.42 per share.
- F6The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.42 to $64.51 per share.
- F7This option was granted on November 21, 2016. This option vested with respect to 25% of the shares underlying the option on November 21, 2017 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.